Navigation Links
Bacterial Infection May Boost SIDS Risk
Date:5/29/2008

udden death could not be explained than from infants whose deaths were explained by non-infectious causes. In particular, S. aureus ("staph") and E. coli had a greater presence in unexplained deaths than in those explained by non-infectious causes.

As an accompanying editorial pointed out, the number of SIDS cases peaks at 8 weeks to 10 weeks of age. That's a time-frame coinciding with blood concentrations of immunoglobulin that protect newborns against bacterial infections.

"This is just at the point that antibodies that go across the placenta -- from mom to baby -- to protect them are starting to disappear, and babies haven't made a lot of their own antibodies yet," noted Dr. Cheryl Cipriani, an associate professor of pediatrics at Texas A&M Health Science Center College of Medicine and a neonatologist with Scott & White. "This is a particular point in time where babies seem to be vulnerable," she said.

Also, both S. aureus and E. coli are bacteria that make toxins, Cipriani explained, "and a toxin might not necessarily cause all the histological changes that you see with infections."

"This is another building block in our knowledge about these kinds of deaths, but association doesn't mean cause," Cipriani cautioned. "But it's a large enough group of babies where you think the findings need to be paid attention to."

Until precise causes for SIDS are uncovered, parents should be aware that putting infants to sleep on their back ("Back to Sleep") reduces the risk of SIDS by 40 percent to 60 percent, Greenberg said. Avoiding your child's exposure to cigarette smoke also reduces this risk.

Using a pacifier might also lower risk, but this is controversial, Greenberg added.

More information

There's more on SIDS at the National Institute of Child Health and Human Development.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Bioniche Updates re: Mycobacterial Cell Wall Technology Platform
2. Do bacterial combinations result in enhanced cytokine production? No!
3. Does Antibacterial Soap Work? At Least One Really Does.
4. Skin Friendly Releases Clinically Proven Hypoallergenic Anti-Bacterial Barrier Lotion
5. Bacterial battle for survival leads to new antibiotic
6. UCF technique promises to aid doctors ability to identify, treat bacterial infections
7. Why recovery from flu may increase odds of bacterial infection
8. Bacterial toxin closes gate on immune response, Penn researchers discover
9. Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
10. Forsyth launches 1-of-a-kind core service to enable rapid identification of bacterial samples
11. First look at an enzyme target for antibacterial and cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bacterial Infection May Boost SIDS Risk
(Date:8/29/2014)... Edvance360, a leading provider of eLearning solutions, ... as well as 2011 winner and six-time-finalist for the ... announced that Brooke Education Services, Northwest Academy, Typewell, Dialysis ... Bureau of Canada (IAB Canada), StarSVCS, and HMG Plus, ... to welcome each new client to the growing Edvance360 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... a U.S. Food and Drug Administration (FDA)-approved treatment ... is as effective at reducing fracture risk as ... suppressing bone loss. With the use of wide- ... researchers carried out experiments at the U.S. Department ... Argonne National Laboratory that revealed an additional mechanism ...
(Date:8/29/2014)... the Washington University School of Medicine have identified one ... providing important insight that could lead to new therapies, ... Cell Host & Microbe . , In work ... Photon Source, the researchers developed a detailed map of ... host protein that takes signaling molecules in and out ...
(Date:8/29/2014)... August 30, 2014 Top10inaction, a professional ... conference providers in the online service industry for the ... global leaders Webex, GotoMeeting and Infinite. , With over ... have to determine which provider is ideally a good ... businesses search for compelling consumer goods and services agencies ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... Blue Plan Experienced a 15 Percent Increase ... a New Report from HealthLeaders-InterStudy, NASHVILLE, ... of managed care market intelligence, reports that ... medication use,through pharmacy programs and public education ...
... Health,Care Systems, Inc. (HCS), a leading provider ... medication reconciliation solutions, has entered,into an agreement with ... not-for-profit hospitals in the nation with 881 licensed,acute ... facility for The,University of Alabama at Birmingham,s Family ...
... treatment could help 3.3 million U.S. sufferers, ... Medical, Inc. today,announced that 98.4 percent of ... called Barrett,s esophagus were free of the ... the HALO ablation,system. The results were published ...
... release of milk in humans, animals , , FRIDAY, July 18 ... speaking? , Researchers have discovered that babies nursing at ... to release of oxytocin, known as the "trust" hormone in ... to be involved in trust and love in both humans ...
... restored brain,s ability to make new cells , , FRIDAY, July ... day may lead to health issues, including depression, a new ... a causal link between abstinence from alcohol drinking and depression," ... and pharmacology in the University of North Carolina School of ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
Cached Medicine News:Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 3Health News:Suckling Infant Triggers 'Trust' Hormone in Moms 2Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
Medicine Products: